Our findings suggest that maintenance treatment of patients with IBD with anti-TNF Abs, but not anti-IL-12/23, impairs and delays affinity maturation of a vaccine-induced Ab response, leading to reduced quantity and quality of GC outputs. The gene discussed is DDX41; the disease is inflammatory bowel disease.